Agios Pharmaceuticals Inc. is tilting at a year-end US approval filing for its first-in-class, oral, targeted inhibitor of the mutant IDH1 enzyme, ivosidenib, for acute myeloid leukemia (AML) as it presented new data at the American Society of Hematology meeting.
Agios' IDH Inhibitors Show Their Mettle At ASH
Updates for key products from Agios bring comfort for analysts as it forges ahead with a filing and new studies in AML. Another of its investigational products is also showing first-in-class potential in pyruvate kinase deficiency.
More from Clinical Trials
More from R&D
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
• By
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.